Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post-hoc analysis of COU-AA-301 and COU-AA-302.

scientific article published on 11 December 2017

Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post-hoc analysis of COU-AA-301 and COU-AA-302. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/ANNONC/MDX759
P698PubMed publication ID29237083

P2093author name stringT Li
K Johnson
D Cella
A Molina
N D Shore
K F Ho
S Traina
P577publication date2017-12-11
P1433published inAnnals of OncologyQ326122
P1476titleRelationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post-hoc analysis of COU-AA-301 and COU-AA-302.

Reverse relations

cites work (P2860)
Q90711328Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion
Q90289244Cancer symptom response as an oncology clinical trial end point
Q58565431Evaluating methodological quality of Prognostic models Including Patient-reported HeAlth outcomes iN oncologY (EPIPHANY): a systematic review protocol
Q64118235Modeling strategies to improve parameter estimates in prognostic factors analyses with patient-reported outcomes in oncology
Q91632011Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
Q99413028Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
Q97530805The prognostic value of pain in castration-sensitive prostate cancer

Search more.